Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
This is a 6-month study to evaluate the effects of monotherapy with rivoglitazone, an insulin
sensitizer, on glycemic control in newly identified type 2 diabetics or diabetics not
adequately treated with other antidiabetic agents. The study tests rivoglitazone and uses a
placebo and active treatment group for comparison.